PCYC News 89.75 Pharmacyclics Inc (PCYC)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pharmacyclics Inc (PCYC) 89.75 $PCYC

'Mad Money' Lightning Round: Blackstone Is On Fire!
at The Street - Thu Apr 17, 5:00AM CDT
Crame doesn't like Gigamon and Southwest Airlines but he's buying Pharmacyclics.

Jim Cramer's 'Mad Money' Recap: Don't Blame the Companies
at The Street - Wed Apr 16, 7:20PM CDT
There's a lot wrong with this market but the companies are part of the solution, not the problem, Cramer asserts.

Pharmacyclics Down 30.9% Since SmarTrend Downtrend Call (PCYC)
Comtex SmarTrend(R) - Tue Apr 15, 4:55PM CDT
SmarTrend identified a Downtrend for Pharmacyclics (NASDAQ CYC) on March 7th, 2014 at $133.00. In approximately 1 month, Pharmacyclics has returned 30.93% as of today's recent price of $91.86.

The Recent Performance of 'Baker Brother Biotech Stocks' is Awful
at The Street - Tue Apr 15, 11:23AM CDT
Healthcare's most closely followed hedge fund is losing money during the biotech bubble burst.

30-Year Ultra Long Gilt Futures Updates, Partnerships, Notes Offer Pricings, and Drug Approvals - Analyst Notes on IntercontinentalExchange, Western Union, Essex Property , Valeant and Pharmacyclics
PR Newswire - Tue Apr 15, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding IntercontinentalExchange, Inc. (NYSE: ICE), The Western Union Company (NYSE: WU), Essex Property Trust Inc. (NYSE: ESS), Valeant Pharmaceuticals International, Inc. (NYSE: VRX) and Pharmacyclics Inc. (NASDAQ: PCYC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1135-100free.

Pharmacyclics (PCYC) Crumbles: Stock Falls by 7.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 10:00AM CDT
Pharmacyclics’ shares fell by nearly 8% yesterday, continuing its downtrend in the past one-month time frame.

Look for Shares of Pharmacyclics to Potentially Rebound after Yesterday's 9.59% Sell Off
Comtex SmarTrend(R) - Thu Apr 10, 5:13PM CDT
Pharmacyclics (NASDAQ CYC) traded in a range yesterday that spanned from a low of $91.18 to a high of $103.44. Yesterday, the shares fell 9.6%, which took the trading range below the 3-day low of $96.15 on volume of 2.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Global B-Cell Non-Hodgkin Lymphoma Clinical Trials Review
M2 - Thu Apr 10, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6w5nm9/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014" report to their offering. B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the B-Cell Non-Hodgkin Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on B-Cell Non-Hodgkin Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating B-Cell Non-Hodgkin Lymphoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - F. Hoffmann-La Roche Ltd. - Celgene Corporation - Takeda Pharmaceutical Company Limited - GlaxoSmithKline plc - Amgen Inc. - Novartis AG - Pharmacyclics, Inc. - Pfizer Inc. - Biogen Idec Inc. - Immunomedics, Inc. Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - Fred Hutchinson Cancer Research Center - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Mayo Clinic - Southwest Oncology Group - Groupe d'Etudes de Lymphomes de L'Adulte - City of Hope National Medical Center - Stanford University For more information visit http://www.researchandmarkets.com/research/6w5nm9/bcell

Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 09, 11:46AM CDT
Last week saw a couple of positive FDA panel votes as well as some disappointing data on experimental drugs.

Pharmacyclics Files sNDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 10:30AM CDT
Pharmacyclics submitted a sNDA to the FDA for Imbruvica.

Pharmacyclics Shares Down 25.2% Since SmarTrend's Sell Call (PCYC)
Comtex SmarTrend(R) - Tue Apr 08, 11:06AM CDT
SmarTrend identified a Downtrend for Pharmacyclics (NASDAQ CYC) on March 7th, 2014 at $133.00. In approximately 1 month, Pharmacyclics has returned 25.19% as of today's recent price of $99.50.

Today’s Top Biotech Stories: Takeda, Eli Lilly, Immunomedics, and Pharmacyclics
Leo Sun, The Motley Fool - Motley Fool - Tue Apr 08, 8:21AM CDT
Let's take a look at four stocks -- Takeda , Eli Lilly , Immunomedics , and Pharmacyclics -- which could make waves in the health care sector this morning. Takeda and Eli Lilly ordered to pay $9 billion for Actos cancer risks ...

Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA with Phase III CLL Study Data
PR Newswire - Tue Apr 08, 7:00AM CDT
Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA), based on data from the randomized, multi-center, open-label Phase III RESONATETM study, PCYC-1112, a head-to-head comparison of single agent IMBRUVICATM (ibrutinib) versus ofatumumab in 391 patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who had received at least one prior therapy. IMBRUVICA is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc.

Pharmacyclics Set to Possibly Pullback After Yesterday's Rally of 7.18%
Comtex SmarTrend(R) - Tue Apr 01, 5:50PM CDT
Pharmacyclics (NASDAQ CYC) traded in a range yesterday that spanned from a low of $100.75 to a high of $110.50. Yesterday, the shares gained 7.2%, which took the trading range above the 3-day high of $108.95 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Pharmacyclics Down 17.7% Since SmarTrend Downtrend Call (PCYC)
Comtex SmarTrend(R) - Tue Apr 01, 9:45AM CDT
SmarTrend identified a Downtrend for Pharmacyclics (NASDAQ CYC) on March 7th, 2014 at $133.00. In approximately 4 weeks, Pharmacyclics has returned 17.70% as of today's recent price of $109.46.

Three Oversold BioTechs for Tired Gamblers: StockTwits.com
at The Street - Mon Mar 31, 10:47AM CDT
Investors seek to play with big-name biotechs after this month's sell-off in the sector. Here are three names that don't promise the lottery payouts of successful small caps, but don't demand betting the house on one drug awaiting approval.

After Yesterday's Decline of 4.46%, Pharmacyclics Offers Investors Better Value
Comtex SmarTrend(R) - Fri Mar 28, 4:04PM CDT
Pharmacyclics (NASDAQ CYC) traded in a range yesterday that spanned from a low of $99.03 to a high of $106.16. Yesterday, the shares fell 4.5%, which took the trading range below the 3-day low of $102.60 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Global Molecular Diagnostics Market 2012-2016: Trends and Collaborations Discussed
M2 - Fri Mar 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mchzgs/global_molecular) has announced the addition of the "Global Molecular Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Molecular Diagnostics market to grow at a CAGR of 11.42 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing investments in genomics and proteomics research. The Global Molecular Diagnostics market has also been witnessing a growth in the diagnostics segment. However, the compliance with regulatory requirements could pose a challenge to the growth of this market. Key vendors dominating this space include Abbott Laboratories, Becton, Dickinson and Co., QIAGEN N.V., and Roche Holding Ltd. Other vendors mentioned in the report are Affymetrix Inc., Agilent Technologies Inc., Alere Inc., AmniSure International LLC, Anadys Pharmaceuticals Inc., Bayer HealthCare AG, Biocartis SA, bioMerieux SA, Bio-Rad Laboratories Inc., Biotest AG, Carmel Pharma AB, Celera Diagnostics LLC, Cellestis Ltd., Cepheid Inc., Cytometers Inc., Danaher Corp., Diagenode SA, Eli Lilly and Co., Eurogentec S.A., Evotec AG, GE Healthcare Ltd., Genomic Health Inc., Gen-Probe Inc., Illumina Inc., Instrumentation Laboratory Co., IRIS International Inc., Janssen Biotech Inc., KIESTRA Lab Automation BV, Life Technologies Corp., Luminex Corp., Merck and Co. Inc., mtm laboratories AG, Nanosphere Inc., Novartis AG, PerkinElmer Inc., Pharmacyclics Inc., PVT Probenverteiltechnik GmbH, Quest Diagnostics Inc., Quidel Corp., Safety Syringes Inc., SANYO North America Corp., Siemens Healthcare, Sirigen Group Limited, St. Jude Medical Inc., Sysmex Corp., and Thermo Fisher Scientific Inc. Commenting on the report, an analyst from the Healthcare team said: 'The Global Molecular Diagnostics market presents several growth opportunities to vendors. Different vendors in the market are increasingly forming strategic alliances with pharmaceutical companies for the development of companion diagnostics, which helps in producing more effective drugs. For instance, in February 2013, Abbott Laboratories collaborated with Janssen Biotech Inc. and Pharmacyclics Inc. to discover the benefits of Abbott's exclusive FISH technology for use in developing a molecular companion diagnostic test to identify patients with chronic lymphocytic leukemia. For more information visit http://www.researchandmarkets.com/research/mc..._molecular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Biotech Stocks Analysis -- Research on Array BioPharma, ACADIA Pharma, Pharmacyclics, and Isis Pharma
PR Newswire - Fri Mar 28, 5:40AM CDT
On Wednesday, March 26, 2014, the NASDAQ Composite ended at 4,173.58, down 1.43%, the Dow Jones Industrial Average fell 0.60% to 16,268.99, and the S&P 500 closed at 1,852.56, down 0.70%. The losses were broad based as nine out of 10 sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 672.05, up 0.05%, and the same has gained 4.63% in the last three months. Investor-Edge has initiated coverage on the following equities: Array BioPharma Inc. (NASDAQ: ARRY), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Pharmacyclics Inc. (NASDAQ: PCYC) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS). Free technical research on ARRY, ACAD, PCYC and ISIS can be downloaded upon signing up at:

Is It Time to Buy These 2 Cancer-Fighting Companies?
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 27, 4:42PM CDT
Investors shouldn't buy and sell shares on market whims and whispers. After all, markets can jump up and down when we least expect it, and that means the chances for predicting its direction over a short period of time is a coin flip, at best. ...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 0

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 24

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 117

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 20

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 231

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 162

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 304

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 229

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 0

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 310

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading

Top 5 Most Recently Viewed Articles

T. Rowe Price OHA Credit Fund Reports Strong Q2 Performance

Updated Category News Views 146

Financial Performance Overview T. Rowe Price OHA Select Private Credit Fund (NASDAQ: OCREDIT) recently reported its financial results for the quarter ended June 30, 2025. The fund declared total distributions amounting to $0.81 per share for this period. This reflects the growing significance of private credit as a financing solution in today's credit markets. Investment...

Continue Reading
Toll Brothers Unveils Luxurious Townhome Community in Armonk

Updated Category News Views 222

Discover the Enclave at Armonk Located in Armonk, the newly launched Enclave at Armonk invites homebuyers to experience luxury living blended with convenience. This new community by Toll Brothers represents a significant addition to the Westchester County real estate market, bringing elegant townhome designs that promise sophistication and comfort. A Closer Look at the...

Continue Reading
XAI Octagon Trust Expands Opportunities with New Preferred Shares

Updated Category News Views 108

XAI Octagon Trust Issues Convertible Preferred Shares XAI Octagon Floating Rate & Alternative Income Trust (NYSE:XFLT), a diversified closed-end management investment company, has made a significant move by announcing the issuance and sale of 400,000 shares of its 6.95% Series II 2029 Convertible Preferred Shares. This initiative enhances the Trust's capital resources and...

Continue Reading
Endeavour Mining's Recent Share Buyback Activity Overview

Updated Category News Views 208

Endeavour Mining Announces Recent Share Buyback In a significant move for shareholders, Endeavour Mining plc (LSE: EDV, TSX: EDV) has disclosed its recent buyback of ordinary shares. These transactions showcase the company's ongoing commitment to enhancing shareholder value and demonstrate a strategic approach to managing its equity. Details of the Share Buyback Endeavour...

Continue Reading
Sleep Awareness Week 2025: Importance of Quality Sleep

Updated Category News Views 459

National Sleep Foundation Announces 2025 Dates for Sleep Awareness Week Today, the National Sleep Foundation (NSF) has shared that Sleep Awareness Week in 2025 will be observed from March 9 to March 15. This annual campaign aims to highlight the critical role sleep plays in promoting health and overall well-being, encouraging the public to prioritize high-quality sleep....

Continue Reading